Europe
Legend, Janssen Will Invest $150M to Expand Carvykti Manufacturing in Europe
The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.
BMS's Breyanzi Gains European Approval as Third-Line Treatment for Follicular Lymphoma
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeating the disease.
MeiraGTx, Hologen Tackle CNS Disorders With AI Drug Development Joint Venture
Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.
European Regulators Warn About Dangers of Unregulated Cell Therapies
The agency advises patients to confirm that any cell, gene, or tissue therapy they receive is approved by a regulator or authorized for use in a clinical trial.
Mar 11, 2025